Teva Pharmaceutical Industries Ltd.

Regulatory Filings • Mar 7, 2025

FORM 4			OMB APPROVAL
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. (Print or Type Responses)	OMB Number: 3235-0287 Estimated average burden hours per response 0.5
1. Name and Address of Reporting Person * Sabag Mark		2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [ TEVA ]	5. Relationship of Reporting Person(s) to Issuer	(Check all applicable)
(Last) (First) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/04/2025	_ Director X __ Officer (give title below)	_ 10% Owner ___ Other (specify below) See "Remarks"
(Street)		4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person
Tel Aviv, L3 6944020			___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

(City) (State) (Zip)

1.Title of Security (Instr. 3)	2. Transaction Date (Month /Day/Year)	2A. Deemed Execution Date, if any	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial
		(Month/Day /Year)	Code	V	Amount	(A) or (D)	Price			Ownership (Instr. 4)
Ordinary Shares (1)	03/04/2025		M		33,512	A	(2)	263,376	D
Ordinary Shares (1)	03/04/2025		M		18,601	A	(2)	281,977	D
Ordinary Shares (1)	03/04/2025		M		183,169	A	(2)	465,146	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month /Day/Year)	3A. Deemed Execution Date, if any (Month/Day /Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially	10. Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)		Date Exercisable Expiration Date	Title	Amount or Number of Shares		Owned Following Reported Transaction (s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)
Restricted Share Units	(2)	03/04/2025		M			33,512	(3)	(3)	Ordinary Shares (1)	33,512	\$ 0	33,512	D
Restricted Share Units	(2)	03/04/2025		M			18,601	(4)	(4)	Ordinary Shares (1)	18,601	\$ 0	55,803	D
Restricted Share Units	(2)	03/04/2025		M			183,169	(5)	(5)	Ordinary Shares (1)	183,169	\$ 0	0	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026.

4. Restricted share units were granted on March 4, 2024, with 18,601 vested on March 4, 2025, and 18,601 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028.

5. Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025.

Remarks:

Executive Vice President, International Markets Commercial

/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag 03/06/2025

Signature of Reporting Person ** Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.